Abridge
Ambient AI clinical documentation for US health systems — real-time medical-conversation transcription, structured clinical-note generation and Epic / Oracle Cerner workflow integration deployed across 200+ health systems including UPMC, Kaiser Permanente, Memorial Hermann and Hennepin Healthcare.
The Business
Abridge builds ambient AI clinical-documentation infrastructure for US health systems — real-time transcription of the in-room patient-clinician conversation, structured clinical-note generation grounded in the Contextual Reasoning Engine and Ghostwriter platform, and deep integration into Epic Hyperdrive / Haiku and Oracle Cerner clinical workflows. The company was founded in 2018 in Pittsburgh by Shiv Rao MD (a practising UPMC cardiologist, founder-CEO and the public face of the company) alongside co-founders Sandeep Konam, Florian Metze and Zachary Lipton. Product surface spans the ambient-scribe core, specialty-tuned documentation flows, and a nursing-AI lane that names OpenAI on the foundation-model side. By the April 2026 Series E extension Abridge had raised more than $616M cumulatively at a $5.3B post-money valuation, with the C-suite fully disclosed during the same evidence window (CTO San Oo, COO Julia Chou, CCO Brian Wilson, CFO Sagar Sanghvi alongside founder-CEO Rao) — the bench-depth print that materially reduced the founder-CEO concentration risk that had constrained the company in earlier years.
Customers and Distribution
Abridge serves 200+ US health systems (250+ in some 2026 sources) with named flagship deployments at UPMC (scaling toward 12,000 clinicians during 2026 — the founder-CEO’s clinical home and the founding reference site), Kaiser Permanente (characterised in press coverage as the industry’s largest generative-AI deployment), Memorial Hermann, Hennepin Healthcare and University Hospitals. The addressable market of approximately 350 large US health systems implies roughly 60% TAM penetration, the metric that drives the P3c GTM-maturity sub-rubric score of 9. Revenue trajectory anchors at $25M (June 2024) to $117M contracted (Q1 2025) with IM-extrapolated ~$250M ARR by April 2026 — a 4x increase over 18 months at a $100M+ ARR base, with an 80% sales-coaching-time reduction disclosed in the Attention case study and “moved beyond pilot phases to full-scale enterprise mandates” framing the pilot-to-enterprise conversion. Distribution rides Epic Hyperdrive / Haiku and Oracle Cerner as the workflow channels, with a mature enterprise GTM function under Chief Commercial Officer Brian Wilson. The 100% US footprint is a deliberate concentration: no UK / EU / APAC expansion has been announced, and the 30% non-English documentation capability target for 2026 addresses multilingual US patient populations rather than international markets.
Model Strategy
Abridge’s defining technical asset is the Contextual Reasoning Engine plus the Ghostwriter platform — the per-health-system tuning and SOP customisation layer that makes the Epic Hyperdrive / Haiku integration a multi-quarter clinical-validation project to replicate, and the principal portability constraint that the D1c portability-and-substitutability sub-rubric scores 8 on. HL7 FHIR-format export is theoretically available as an industry standard, but per-system Contextual Reasoning Engine tuning and Ghostwriter-style SOP customisation make migration a workflow-validation project rather than a configuration switch. Foundation-model strategy is multi-model-routing in posture, with OpenAI named for the nursing-AI lane and other model providers implied but not contractually disclosed — the D4a supplier-diversity sub-rubric scores 6 on this evidence with an [INFERRED] flag pending fresh hyperscaler and FM-routing disclosure. Infrastructure runs on HIPAA-compliant US-based data centres with 256-bit encryption at rest and in transit, SOC 2 Type II certification, and a public BAA — the regulatory perimeter that the D4c regulatory-exposure sub-rubric scores 4 on against the 2026 HIPAA Security Rule changes and active state-level AI-in-clinical-care rulemaking. Best in KLAS 2026 recognition for ambient speech is the strongest independently-benchmarked positioning print in the cohort to date.
At A Glance
The Numbers
Annualised revenue
Contracted clinicians
Headcount (FTE)
Funding to date
Leadership Team
Co-founders Sandeep Konam, Florian Metze and Zachary Lipton remain on the cap table; Rao is the operational founder-CEO and public-facing figure. The April 2026 C-suite disclosure (CTO, COO, CCO, CFO all publicly named) was the principal evidence-pass change that drove the D4e key-person-dependency sub-rubric upgrade from 6 to 7.
IM Framework Scoring
IM’s structured assessment of Abridge’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Apr 2026 | Series E extension | ~$316M | $5.3B | Undisclosed (extension of June 2025 round) |
| Jun 2025 | Series E | $300M | $5.3B | Andreessen Horowitz, Khosla Ventures |
| Feb 2025 | Series D | $250M | $2.75B | Elad Gil, IVP |
| Feb 2024 | Series C | $150M | ~$850M | Lightspeed Venture Partners, Redpoint Ventures |
| 2023 | Series B | ~$30M | — | Bessemer Venture Partners |
| 2018 | Seed / Series A | Undisclosed | — | UPMC Enterprises, Bessemer Venture Partners |
Cumulative >$616M raised through the April 2026 Series E extension at $5.3B post-money — capital-efficiency ratio approximately 7.5x (valuation / total raised). The June 2025 Series E doubled valuation from $2.75B (Series D, February 2025) in four months. Round-by-round figures from Abridge press releases, TechCrunch, Becker’s Hospital Review and TechJack coverage. Note that the April 2026 Series E extension lead was not publicly disclosed at time of writing.
Competitive Landscape
Abridge’s competitive set sits in three concentric rings: incumbent ambient-scribe / clinical-documentation platforms (DAX Copilot / Microsoft-Nuance and Suki AI), adjacent ambient and remote-scribe plays now owned by larger health-tech parents (Augmedix inside Commure), and the hyperscaler healthcare-vertical platform (Microsoft Cloud for Healthcare) that can bundle ambient documentation with broader infrastructure. The standout flanking risk is Heidi Health on the SMB / mid-market and international segments Abridge under-serves.
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| DAX Copilot (Microsoft (Nuance)) |
Ambient clinical documentation grounded in the Nuance Dragon Medical legacy installed base; rebuilt as DAX Copilot under Microsoft post the Nuance acquisition. The incumbent ambient-scribe in the US health-system market. | Microsoft enterprise sales motion plus the Nuance Dragon Medical installed base across US health systems; Azure-native deployment. | High — the symmetric incumbent on health-system procurement; deepest installed-base distribution and the strongest channel competing for the same Epic / Oracle Cerner integration slot. |
| Suki AI | AI clinical-documentation assistant with a workflow-assistant framing rather than ambient-only; supports clinician dictation, ambient scribing and EHR-task automation. | Direct to health-system IT and clinician channels; partnerships with Epic, Oracle Cerner, MEDITECH and athenahealth on documentation workflows. | High — the closest independent rival on capability and EHR-integration breadth; competes head-to-head on the ambient-scribe selection committee. |
| Augmedix (Commure (acquired Jul 2024)) |
Remote-scribe and ambient AI documentation; combines human medical documentation specialists with AI assistance. Acquired by Commure for ~$139M in July 2024. | Commure’s broader US health-system go-to-market with embedded clinical-workflow software; long-running health-system contracts inherited from Augmedix’s independent years. | Medium — the human-plus-AI model is structurally higher cost per encounter than pure-ambient AI; threat is the Commure-channel breadth rather than the standalone product. |
| Heidi Health | Ambient AI medical scribe with a faster self-serve onboarding motion than the enterprise health-system incumbents; clinician-direct distribution including SMB and mid-market practices. | Self-serve and direct-to-clinician GTM; international footprint (Australia, UK, US) that is differentiated against the US-centric Abridge positioning. | Medium — flanking risk on the SMB / mid-market segment Abridge under-serves, and on international clinician adoption where Abridge has no announced presence. |
| Microsoft Cloud for Healthcare (Microsoft (NASDAQ: MSFT)) |
Healthcare-vertical cloud platform layering DAX Copilot, Fabric for healthcare data, Azure AI Foundry healthcare agents and the Dragon Copilot brand across the Nuance and Microsoft 365 estate. | Microsoft enterprise channels with deep US health-system relationships through the Nuance Dragon Medical and Microsoft 365 footprints. | High and asymmetric — not a like-for-like competitor but a hyperscaler-vertical platform that can bundle DAX Copilot with broader healthcare-AI capabilities at a price point Abridge cannot match standalone. |
Pricing benchmark: ambient-scribe pricing in the US health-system market is generally enterprise-negotiated per-clinician-per-month, with reported figures clustered in the $200-600 / clinician / month range for the named-incumbent set; Abridge has not publicly disclosed list pricing. The competitive cut is on Epic Hyperdrive / Haiku integration depth, Contextual Reasoning Engine and Ghostwriter customisation per health system, and Best in KLAS positioning rather than headline per-seat price.
Potential Risks
The case for Abridge at IM Framework 7.54 rests on the 200+ US health-system installed base (~60% TAM penetration), top-decile capital position (>$616M raised at $5.3B post-money), 4x revenue growth over 18 months, and the full C-suite disclosure that materially reduced founder-CEO concentration. The case against splits into five risks of differing magnitude — with the symmetric-incumbent head-to-head with DAX Copilot the most active and the 2026 HIPAA Security Rule rulemaking the most structural framing constraint.
Symmetric-incumbent head-to-head — DAX Copilot on health-system procurement
Microsoft-Nuance’s DAX Copilot competes for the same Epic Hyperdrive / Haiku integration slot and the same ambient-scribe procurement cycle inside US health systems, backed by the deepest installed base (the Nuance Dragon Medical legacy footprint) and the broader Microsoft Cloud for Healthcare bundle. Abridge wins on capability and Best in KLAS 2026 positioning today; the incumbent wins on distribution and bundle economics if the capability gap narrows. The risk is procurement-cycle defaulting to the incumbent on multi-product Microsoft renewals.
Regulatory exposure — HIPAA Security Rule 2026 changes and AI-in-clinical-care state rulemaking
Abridge is HIPAA-compliant, SOC 2 Type II certified, with US-based data centres, 256-bit encryption at rest and in transit, and a public BAA. The 2026 HIPAA Security Rule changes flagged industry-wide require increased cybersecurity investment for HIPAA-regulated entities, and clinical-documentation AI sits in an evolving regulatory grey zone with active state-level AI-in-clinical-care rulemaking. No FDA approval is disclosed; the regulatory perimeter is the operational risk that the D4c sub-rubric scores 4 on.
Geopolitical concentration — 100% US footprint
Abridge has no UK / EU / APAC expansion announced; the 30% non-English documentation capability target for 2026 is multilingual support inside US patient populations rather than international expansion. US healthcare-AI rulemaking is the binding constraint, and Heidi Health’s international footprint (Australia, UK, US) is the flanking exemplar of what international clinician distribution can look like. The D4f sub-rubric scores 4 on this evidence.
Valuation-to-revenue ratio and 2026 capital-markets compression risk
$5.3B valuation on IM-extrapolated ~$250M ARR is approximately 21x — a premium multiple justified by the 4x revenue growth over 18 months and the ~60% TAM penetration of the ~350 large-health-system addressable market, but with compression risk if growth slows or if DAX Copilot or Suki AI materially close the capability gap. The June 2025 Series E doubled valuation from the February 2025 Series D in four months; the April 2026 Series E extension held that valuation. Compression-risk window opens at the next priced round.
Hyperscaler-supplier opacity and FM-routing disclosure
Abridge runs on HIPAA-compliant US-based data centres but neither AWS nor Azure is publicly named as the hyperscaler; FM-routing names OpenAI for the nursing-AI lane but multi-model routing is implied rather than contractually disclosed. The D4a supplier-diversity sub-rubric scores 6 on this evidence with an `[INFERRED]` flag. Public hyperscaler and FM-routing disclosure would materially lift this; the absence is a residual-risk source on supplier concentration and on FM-capability dependence.
Recent IM Coverage
Show recent press coverage of Abridge
- Apr 2026 — Abridge closes reported $316M Series E extension at $5.3B valuation.
- Mar 2026 — Abridge named Best in KLAS 2026 for ambient speech.
- 2026 — UPMC scales Abridge to 12,000 clinicians: founding-health-system reference deployment.
- Jun 2025 — In just 4 months, AI medical scribe Abridge doubles valuation to $5.3B.
- Jun 2025 — Abridge closes $300M in Series E funding, hits $5.3B valuation.
- 2026 — Attention highlights Abridge revenue growth and sales efficiency gains — 4x revenue growth over 18 months, 80% sales-coaching-time reduction.
- 2026 — Abridge company profile and ARR trajectory analysis.
Curated feed of named-source coverage from approved publications — Abridge’s own press releases, named-author healthcare-IT press (Becker’s Hospital Review), tier-1 tech press (TechCrunch), and analyst-research disclosures (Sacra, TipRanks, TechJack). We exclude PR-wire reposts of the same release and unsourced “industry round-up” pieces.
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue — ARR trajectory: Sacra company profile records the ARR trajectory from $25M (Jun-24) to $117M contracted (Q1-25), with IM-extrapolated ~$250M by Apr-26 anchored on the 4x revenue growth disclosed by the Attention case study — see Sacra Abridge profile and TipRanks coverage of the Attention case study. Abridge has not separately disclosed a primary ARR figure for FY2026.
- Customer base — 200+ US health systems: Abridge discloses 200+ US health-system deployments including UPMC scaling to 12,000 clinicians and Kaiser Permanente’s industry-largest generative-AI project — see Abridge UPMC scale-out press release and the Abridge About page. Best in KLAS 2026 recognition per Abridge press release.
- Leadership — full C-suite disclosure: CEO Shiv Rao per the Abridge CEO bio; CTO San Oo, COO Julia Chou, CCO Brian Wilson, CFO Sagar Sanghvi per the Abridge About page and Craft.co executives index (soft-corroboration only on the executives index). Co-founders Sandeep Konam, Florian Metze and Zachary Lipton remain on the cap table.
- Funding to date — >$616M raised at $5.3B post-money: $300M Series E at $5.3B closed June 2025 per Becker’s Hospital Review and the TechCrunch coverage of the doubling from $2.75B Series D. $316M Series E extension at $5.3B reported April 2026 per TechJack; the extension lead was not publicly disclosed at time of writing.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
